Supplements
boswellia prevents cancer
In plain terms: Does boswellia fight cancer?
Leans support(preclinical) Supplements 🐭 Non-human evidence
Part of: 🧪 boswellia
RefutedContestedStrong support
consensus score 0.72
🔬 Capped to leans support — preclinical evidence only. The raw signal looked like strong support, but a claim about human health can't be graded that high on animal or lab evidence alone. It stays capped until human trials weigh in.
No human evidence. Boswellic acids slow cancer cells in a dish, but nothing shows boswellia prevents or treats cancer in people. (It has been shown to reduce radiation-related brain swelling — an anti-inflammatory effect, not an anti-cancer one.)
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
8 support 0 contradict 0 tested null 3 mixed · 11 sources, 8 independent groups
What the evidence shows
Lab-only. Boswellic acids show antiproliferative activity against cancer cells in vitro, but there is no human evidence that boswellia prevents or treats cancer. (Note: a human trial did show boswellia reduces radiation-related brain swelling in cancer patients — an anti-inflammatory effect, not an anti-cancer one.)
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Qayum U et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: MDA-MB-231 breast cancer cells. Boswellia sacra stem/leaf essential oils showed moderate antiproliferative IC50 (~89-92 ug/mL), incidental to the study's primary antidiabetic/antimicrobial focus. |
| Eid AM et al 2026 · BioMed Research International | in-vitro | mixed | low | MTS cytotoxicity, 72 h, ~10^3 cells/well in triplicate, doses 125-1000 ug/mL; two test articles - neat B. sacra steam-distilled essential oil AND a topical nanoemulgel of it ('Formulation 1, which had a composition of 35% Tween 80, 15% Span 80, and 50% B. sacra oil, a PDI of 0.211, and a droplet size of 120.03 nm', gelled in 0.4% Carbopol). Nanoemulgel IC50 (ug/mL): HepG2 79.43, 3T3 107.15, MCF-7 128.82, HeLa 186.2, LX-2 186.2; neat oil: HepG2 112.2, 3T3 190.54, MCF-7 196.33, LX-2 436.51, HeLa 466.65. STANCE MIXED rather than supports, on the paper's own numbers. (1) Only three of the five lines are malignant: the Methods describe 'human male hepatic stellate (LX-2; PRID: CVCL_5792), which is a liver hepatic stellate cell' and 'a mouse embryo fibroblast cell line (3 T3; RRID:CVCL_0121)', while the abstract calls all five 'cancerous cells' - the framing the previous extract inherited. (2) No selectivity for malignancy was shown: the non-malignant 3T3 fibroblast was the SECOND most sensitive line to both preparations, killed at lower concentrations than MCF-7 or HeLa, whereas the positive control did discriminate - 'The impact of nanoemulgel and oil on 3 T3 cells was observed, yielding IC 50 values of 107.15 and 190.54 ug/mL, respectively, compared with the positive control DOX with an IC50 of 1.55 +/- 1.35, 0.434 +/- 0.271, 0.001 +/- 0.0013, 0.05 +/- 0.012 and 8.15 +/- 2.09 ug/mL for HeLa, Hep-G2, MCF, LX-2, and 3 T3, respectively' (doxorubicin is 10-80,000x more potent and least active on the fibroblast). The authors concede the gap: 'Despite the promising results of the B. sacra nanoemulgel, a limitation of this study is the absence of cytotoxicity tests on normal human cell lines.' (3) Reliability limits on the headline numbers: 'The culture medium was replaced with a new formulation that maintained the same base but included varying concentrations of B. sacra oil and B. sacra oil nanoemulgel (125, 250, 500, and 1000 ug/mL)' - so the 79.43 and 107.15 IC50s sit BELOW the lowest dose actually given and are extrapolated; and the nanoemulgel's apparent advantage over the oil has no drug-free-vehicle arm here (the blank emulgel control, 'Hole D was then filled with emulgel without using B. sacra oil', was run only in the agar antimicrobial assay and its result is never reported), although the nanoemulsion is half Tween 80/Span 80. On-scope: the neat-oil arm is reported separately, and this claim's evidence set already holds B. sacra / B. serrata essential-oil in-vitro work on-scope (s41771798, s41853213). Quality stays low - single lab, no statistics, no replication, low-selectivity venue. Eid AM, Naseef H, Abualhasan M, Yassin D, Jaber S, Abu Gazaleh A, BioMed Research International 2026;7034598, doi 10.1155/bmri/7034598. 'Funding No funding was received for this manuscript. Conflicts of Interest The authors declare no conflicts of interest.' |
| Jamshidi-Adegani F et al 2026 · study_type: animal | animal | supports | moderate | Cell model SK-MEL-28 melanoma cells plus in vivo B16F10 mouse melanoma model. Incensole (Boswellia diterpene) induced p53-mediated apoptosis, inhibited migration, reduced tumor burden/metastasis and remodeled macrophage polarization in mice |
| Ragab W et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Cell model: HepG2 liver cancer cells. Frankincense aqueous extract combined with sorafenib produced strong synergistic cytotoxicity (CI=0.298), enhanced apoptosis/necrosis, autophagy activation, and reduced migration versus either agent alo |
| Khan SN et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: ovarian cancer lines A2780-S/A2780-CP and HUVEC. Synthetic triazole-metronidazole-boswellic acid hybrid derivatives showed enhanced selective cytotoxicity versus parent triterpenoids, with molecular docking to PARP6. |
| Kamalabadi-Farahani M et al 2025 · study_type: in-vitro | in-vitro | supports | low | Cell model: primary (4T1T) and brain-metastatic (4T1B) mouse breast cancer cell lines. Frankincense methanolic extract showed cytotoxic, apoptotic, and anti-metastatic (MMP-2/9 suppressing) effects, more pronounced in metastatic cells. |
| Al-Yasiry 2016 · Postepy Hig Med Dosw | observational | mixed | low | Review: anticancer activity of boswellic acids is described in vitro/in animals; no human prevention evidence. |
| Mazzio 2017 · Cancer Genomics Proteomics | in-vitro | mixed | low | In-vitro: boswellia altered gene expression / antiproliferative signalling in breast-cancer cells (preclinical). |
| Nigussie G et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: MCF-7 breast cancer cells. Boswellia neglecta stem methanol extract showed significant cytotoxicity (27% viability at 200 ug/mL) alongside antibacterial/antiviral/antioxidant effects. |
| Bonucci M et al 2025 · study_type: observational | observational | mixed | low | Human model: prospective non-randomized pilot in 72 glioblastoma patients; those adherent to an integrative regimen of polydatin, curcumin, AND Boswellia serrata (plus standard chemoradiotherapy) had longer median overall survival (25.4 vs |
| Fatima A et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Systematic literature review (PubMed/Web of Science/Scopus 2012-2025) of boswellic acids' anticancer activity, concluding potent activity against numerous cancer cell lines in preclinical (cell-line) studies, limited by bioavailability. |
| d10-1016-j-nxmate-2026-102712 2026 · Next Materials | in-vitro | supports | low | Cell model: HepG2 hepatocellular carcinoma cells. Pterostilbene-frankincense-essential-oil-loaded PLGA nanoparticles showed dose-dependent cytotoxicity (IC50 46.8 ug/mL) versus free pterostilbene (94.6 ug/mL). |
| Zhang J et al 2026 · study_type: in-vitro | in-vitro | supports | low | Cell model: MDA-MB-231 breast cancer cells. Boswellia serrata essential oil showed antiproliferative/apoptosis-inducing cytotoxicity (IC50 ~99-165 ug/mL) and synergized with doxorubicin. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.